Cancer statistics, 2013

  title={Cancer statistics, 2013},
  author={Rebecca L. Siegel and Deepa Naishadham and Ahmedin Jemal},
  journal={CA: A Cancer Journal for Clinicians},
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival based on incidence data from the National Cancer Institute, the Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries and mortality data from the National Center for Health Statistics. A total of 1,660,290 new cancer cases… 

Pancreatic cancer death rates by race among US men and women, 1970-2009.

In the United States, whites and blacks experienced opposite trends in pancreatic cancer death rates between 1970 and 2009 that are largely unexplainable by known risk factors.

Breast cancer statistics, 2013

An overview of female breast cancer statistics in the United States, including data on incidence, mortality, survival, and screening is provided, with African American women having the poorest breast cancer survival of any racial/ethnic group.

European cancer mortality predictions for the year 2013.

Favourable trends will continue in 2013 except for pancreatic cancer and lung cancer in women, while in a few years lung cancer will likely become the first cause of cancer mortality in women as well, overtaking breast cancer.

Cancer mortality in Europe, 2005-2009, and an overview of trends since 1980.

With the major exceptions of female lung cancer and pancreatic cancer in both sexes, cancer mortality has moderately but steadily declined across Europe in the last quinquennium, requiring targeted interventions on risk factor control, early diagnosis, and improved management and pharmacological treatment for selected cancer sites.

Operative Management of Metastatic Breast Cancer

The decline in mortality can be attributed to two factors: the first is a better understanding of and adherence to screening guidelines, and the second is the advances made in the systemic treatment of breast cancer patients.

European cancer mortality predictions for the year 2014.

Cancer mortality predictions for 2014 confirm the overall favorable cancer mortality trend in the EU, translating to an overall 26% fall in men since its peak in 1988, and 20% in women, and the avoidance of over 250,000 deaths in 2014 compared with the peak rate.

Trends in UK regional cancer mortality 1991–2007

Mortality from the four most common cancers decreased across all regions of the United Kingdom; however, the rate of decline varied between cancer type and in some instances by region.

The global challenge of reducing breast cancer mortality.

After being on a plateau for decades, breast cancer mortality began falling in a number of countries in about 1990, but in some countries such as Sweden as early as 1975, these declines have mainly occurred where either or both of two effective interventions had been introduced into routine management of breast cancer: adjuvant therapy and mammographic screening.



Trends in Breast Cancer by Race and Ethnicity

Trends in incidence, mortality, and survival rates of female breast cancer in the United States by race and ethnicity are described and continued efforts are needed to increase the availability of high‐quality mammography and treatment to all segments of the population.

Annual Report to the Nation on the Status of Cancer, 1975–2005, Featuring Trends in Lung Cancer, Tobacco Use, and Tobacco Control

Although the decrease in overall cancer incidence and death rates is encouraging, large state and regional differences in lung cancer trends among women underscore the need to maintain and strengthen many state tobacco control programs.

Impact of reporting delay and reporting error on cancer incidence rates and trends.

Investigating the impact of reporting delay and reporting error on incidence rates and trends for cancers of the female breast, colorectal, lung/bronchus, prostate, and melanoma found reporting-adjusted cancer incidence rates are valuable in precisely determining current cancer incidence levels and trends and in monitoring the timeliness of data collection.

A New Method of Estimating United States and State‐level Cancer Incidence Counts for the Current Calendar Year

A new method is presented that uses statistical models of cancer incidence that incorporate potential predictors of spatial and temporal variation of cancer occurrence and that account for delay in case reporting and then projects these estimated numbers of cases ahead 4 years using a piecewise linear (joinpoint) regression method.

Annual Report to the Nation on the status of cancer, 1975‐2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer

The American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR)

Cancer Disparities by Race/Ethnicity and Socioeconomic Status

Differences in cancer incidence, mortality, and survival in relation to race/ethnicity, and census data on poverty in the county or census tract of residence are highlighted.

Annual report to the nation on the status of cancer, 1975‐2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates

This year's report includes trends in colorectal cancer incidence and death rates and highlights the use of microsimulation modeling as a tool for interpreting past trends and projecting future trends to assist in cancer control planning and policy decisions.

Deaths: final data for 2009.

The decline of the age-adjusted death rate to a record low value for the United States and the increase in life expectancy to arecord high value of 78.5 years are consistent with long-term trends in mortality.

Quantifying the role of PSA screening in the US prostate cancer mortality decline

PSA screening may account for much, but not all, of the observed drop in prostate cancer mortality, and other factors, such as changing treatment practices, may also have played a role in improving prostate cancer outcomes.

Effect of screening and adjuvant therapy on mortality from breast cancer.

Seven statistical models showed that both screening mammography and treatment have helped reduce the rate of death from breast cancer in the United States.